ALM 27134
Alternative Names: ALM-27134; Anti-human IL1RAP antagonist mAb; Anti-IL-1RAP mAb - Almirall S.A; ISB-880Latest Information Update: 25 Aug 2025
At a glance
- Originator Ichnos Sciences
- Developer Almirall S.A.
- Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders; Hidradenitis suppurativa
Most Recent Events
- 25 Jul 2025 Almirall completes a phase I trial in Hidradenitis suppurativa (In volunteers) (Parenteral)
- 25 Jul 2025 Adverse events data from a phase I trial in Hidradenitis suppurativa released by Almirall
- 24 Feb 2025 Phase-I clinical trials in Hidradenitis suppurativa (In volunteers) (Parenteral) before February 2025